Eftozanermin alfa is under clinical development by AbbVie and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Eftozanermin alfa’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Eftozanermin alfa overview
Eftozanermin alfa (ABBV-621) is under development for the treatment of hematological malignancies such as relapsed or refractory multiple myeloma, acute myeloid leukemia and non-Hodgkin lymphoma including diffuse large B-cell Lymphoma and solid tumors such as colorectal cancer and pancreatic cancer. It is administered through the intravenous route. It is a fully human Fc-fusion protein consisting of two single-chain TRAIL-molecules fused covalently to the Fc portion of a human IgG molecule. It is based on TNFSF Technology. It targets tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 1, 2.
AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic diseases, rheumatological diseases, neurological disorders, viral diseases, skin diseases, complications associated with cystic fibrosis, pain related to endometriosis, diseases of the gastrointestinal tract, various types of cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of cystic fibrosis, women’s health, various cancers, neurological disorders and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.
For a complete picture of Eftozanermin alfa’s drug-specific PTSR and LoA scores, buy the report here.